Trial Profile
A Study to Estimate the Immune Response Following a Challenge Dose in Adults (>=50 Years Old) Vaccinated With a Primary Series of an Hepatitis B Vaccine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme; sanofi pasteur MSD
- 11 Oct 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.go.